Jacobs Levy Equity Management
TCRX icon

Jacobs Levy Equity Management’s TScan Therapeutics TCRX Stock Holding History

Jacobs Levy Equity Management’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.03M Buy
1,049,806
+241,450
+30% +$257K ﹤0.01% 705
2026
Q1 		$816K Buy
808,356
+620,204
+330% +$663K ﹤0.01% 747
2025
Q4 		$188K Buy
+188,152
New +$272K ﹤0.01% 887
2025
Q1 		– Sell
-18,951
Closed -$57.6K – 1197
2024
Q4 		$57.6K Sell
18,951
-84,489
-82% -$383K ﹤0.01% 922
2024
Q3 		$515K Buy
+103,440
New +$624K ﹤0.01% 828

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Jacobs Levy Equity Management's TCRX Position: Q2 2026 in Review

Jacobs Levy Equity Management increased its TScan Therapeutics (TCRX) stake by 30% in Q2 2026, buying an estimated $257K and bringing the position to 1,049,806 shares worth $1.03M. The position accounts for ﹤0.01% of the portfolio, ranked #705.

Jacobs Levy Equity Management first reported a position in TCRX in Q3 2024 and has held it in 5 quarters since. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

  • Jacobs Levy Equity Management held 1,049,806 shares of TScan Therapeutics worth $1.03M as of Q2 2026.
  • Jacobs Levy Equity Management bought 241,450 TScan Therapeutics shares in Q2 2026, an estimated $257K.
  • TScan Therapeutics made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #705 holding.
  • Jacobs Levy Equity Management first reported a position in TScan Therapeutics in Q3 2024 and has held it in 5 quarters since.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.